297 related articles for article (PubMed ID: 35224018)
1. Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?
Shmais M; Regueiro M; Hashash JG
Inflamm Intest Dis; 2022 Jan; 7(1):50-58. PubMed ID: 35224018
[TBL] [Abstract][Full Text] [Related]
2. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.
Nigam GB; Chatten K; Sharara A; Al-Taweel T; Alharbi O; Elamin H; Al Awadhi S; Annese V; Limdi JK
Therap Adv Gastroenterol; 2024; 17():17562848241230902. PubMed ID: 38406794
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Papamichael K; Cheifetz AS
Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
[TBL] [Abstract][Full Text] [Related]
4. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
5. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
Porth R; Deyhim T; Zullow S; Rabinowitz LG; Grossberg LB; Roblin X; Paul S; Cheifetz AS; Papamichael K
Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953651
[TBL] [Abstract][Full Text] [Related]
6. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
[TBL] [Abstract][Full Text] [Related]
7. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Papamichael K; Cheifetz AS
Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
[TBL] [Abstract][Full Text] [Related]
9. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
11. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease.
Vaughn BP
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768509
[TBL] [Abstract][Full Text] [Related]
12. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis.
Zheng FY; Yang KS; Min WC; Li XZ; Xing Y; Wang S; Zhang YS; Zhao QC
World J Gastrointest Surg; 2024 Feb; 16(2):571-584. PubMed ID: 38463352
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.
Vande Casteele N; Feagan BG; Wolf DC; Pop A; Yassine M; Horst SN; Ritter TE; Sandborn WJ
Inflamm Bowel Dis; 2021 Jul; 27(8):1346-1355. PubMed ID: 33051647
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
15. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
[TBL] [Abstract][Full Text] [Related]
16. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease.
Ma C; Battat R; Jairath V; Vande Casteele N
Curr Treat Options Gastroenterol; 2019 Mar; 17(1):127-145. PubMed ID: 30680599
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
[No Abstract] [Full Text] [Related]
18. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
van Hoeve K; Hoffman I; Vermeire S
Expert Opin Drug Saf; 2018 Feb; 17(2):185-196. PubMed ID: 29202588
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
